In the U31402-A-J101 phase I/II study of HER3-DXd in HER3-expressing ABC, ORR was 30.1% with mPFS of 7.4 months in the HR + /HER2− cohort, despite being heavily pretreated (Table 4)107. The gene discussed is HR; the disease is aneurysmal bone cyst.